Efficacy and Tolerability of Histamine-2 Receptor Antagonist Adjunction of Antipsychotic Treatment in Schizophrenia: A Meta-analysis of Randomized Placebo-controlled Trials

Abstract

Introduction: No comprehensive meta-analysis has been performed concerning the efficacy and tolerability of adjunctive therapy with histamine-2 receptor antagonists (H₂R-ANTs) in schizophrenia patients who were treated with antipsychotics.

Methods: Risk ratios, standardized mean differences (SMD), and 95% confidence intervals were calculated.

Results: We included 8 double-blinded, randomized placebo-controlled trials (RCTs) (n=418) that met the inclusion criteria (famotidine: N=3, n=74; nizatidine: N=4, n=292; ranitidine: N=1, n=52). Pooled H₂R-ANTs were not different from placebo with regard to reduction in overall symptoms and body weight. However, pooled H₂R-ANTs resulted in lower body mass index (BMI) than placebo (SMD=−0.68). Moreover, nizatidine was associated with an increase in plasma leptin levels (SMD=− 1.14). There were no significant differences in the discontinuation rates due to all-cause, side effects, and inefficacy between pooled H₂R-ANTs and placebo. However, nizatidine produced more depression and dry mouth than placebo.

Discussion: H₂R-ANT adjunctive therapy did not improve overall symptoms. To clarify the opposite results between body weight and BMI, future research should investigate long-term efficacy and generate more safety data by using larger samples.

Key words

histamine-2 receptor antagonists - schizophrenia - weight gain - psychopathology - leptin - systematic review - meta-analysis

• References

• 1 De Hert M, Vancampfort D, Correll CU et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 2011; 199: 99-105
• 2 Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962
• 3 Correll CU, Manu P, Olshanskiy V et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-1773
• 4 Kishi T, Matsuda Y, Nakamura H et al. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatric Res 2013; 47: 149-154
• 5 Jacobson BC. Body mass index and the efficacy of acid-mediating agents for GERD. Dig Dis Sci 2008; 53: 2313-2317
• 6 Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1-4
• 7 Lett TA, Wallace TJ, Chowdhury NI et al. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 2012; 17: 242-266
• 8 Stip E, Lungu O, Anselmo K et al. Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl Psychiatry 2012; 2: e128 doi: 10.1038/tp.2012.53
• 9 Farzin D, Hosseini S, Shafaat A. A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia. Iran J Med Sci 2005; 30: 59-62
• 10 Meskanen K, Ekelund H, Laitinen J et al. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. J Clins Pychopharmacol 2013; 33: 472-478
• 11 Poyurovsky M, Tal V, Maayan R et al. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. Eur Neuropsychopharmacol 2004; 14: 332-336
• 12 Assuncao SS, Ruschel SI, Rosa Lde C et al. Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine. Rev brasil psiquiatria 2006; 28: 270-276
• 13 Atmaca M, Kuloglu M, Tezcan E et al. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. Hum Psychopharmacol 2003; 18: 457-461
• 14 Atmaca M, Kuloglu M, Tezcan E et al. Nizatidine for the treatment of patients with quetiapine-induced weight gain. Hum Psychopharmacol 2004; 19: 37-40
• 15 Cavazzoni P, Tanaka Y, Roychowdhury SM et al. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2003; 13: 81-85
• 16 Ranjbar F, Ghanepour A, Sadeghi-Bazargani H et al. The effect of ranitidine on olanzapine-induced weight gain. BioMed Res Int 2013; 2013: 639391
• 17 Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Supplement 1989; DOI: 59-67
• 18 Guy W, Bonato RR. Manual for the ECDEU Assessment Battery. 2nd ed. Chevy Chase, Md: National Institute of Mental Health; 1970. DOI
• 19 Mizuno Y, Suzuki T, Nakagawa A et al. Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bull 2014; DOI: 10.1093/schbul/sbu030.
• 20 Cohn LD, Becker BJ. How meta-analysis increases statistical power. Psychol Meth 2003; 8: 243-253
• 21 Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535
• 22 Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812
• 23 Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta psychiatrica Scand Suppl 1970; 212: 11-19
• 24 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials 1986; 7: 177-188
• 25 Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560